Premium
SIZE REDUCTION OF A PROLACTIN SECRETING ADENOMA DURING LONG‐TERM TREATMENT WITH THE DOPAMINE AGONIST LISURIDE
Author(s) -
CHIODINI P. G.,
LIUZZI A.,
VERDE G.,
COZZI R.,
SILVESTRINI F.,
MARSILI M. T.,
HOROWSKI R.,
PASSERINI F.,
LUCCARELLI G.,
BORGHI P. G.
Publication year - 1980
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1980.tb03131.x
Subject(s) - lisuride , prolactin , dopamine agonist , endocrinology , medicine , agonist , prolactinoma , dopamine , adenoma , galactorrhea , dopamine receptor , hormone , receptor
SUMMARY A 38–year‐old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by carotid angiography and computed axial tomography (CAT), was treated with a dopamine agonist (lisuride). PRL levels were lowered and after 1 year of treatment CAT showed a marked reduction of the tumour size. After 2 years of treatment menstruation returned and CAT demonstrated a further reduction of the adenomatous tissue. This study supports the suggestion that dopamine agonists possess an anti‐pro‐liferative effect on tumoural lactotrophic cells of humans.